- Home
- QSI vs PLRX Comparison
QSI vs PLRX Comparison
Compare QSI & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- PLRX
- Stock Information
- Founded
- QSI 2013
- PLRX 2015
- Country
- QSI United States
- PLRX United States
- Employees
- QSI N/A
- PLRX N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- PLRX Health Care
- Exchange
- QSI Nasdaq
- PLRX Nasdaq
- Market Cap
- QSI 226.8M
- PLRX 89.0M
- IPO Year
- QSI N/A
- PLRX 2020
- Fundamental
- Price
- QSI $1.18
- PLRX $1.59
- Analyst Decision
- QSI Strong Buy
- PLRX Hold
- Analyst Count
- QSI 3
- PLRX 10
- Target Price
- QSI $2.38
- PLRX $3.93
- AVG Volume (30 Days)
- QSI 5.3M
- PLRX 884.9K
- Earning Date
- QSI 11-11-2025
- PLRX 11-06-2025
- Dividend Yield
- QSI N/A
- PLRX N/A
- EPS Growth
- QSI N/A
- PLRX N/A
- EPS
- QSI N/A
- PLRX N/A
- Revenue
- QSI $3,412,000.00
- PLRX N/A
- Revenue This Year
- QSI $45.62
- PLRX N/A
- Revenue Next Year
- QSI $218.03
- PLRX N/A
- P/E Ratio
- QSI N/A
- PLRX N/A
- Revenue Growth
- QSI 100.47
- PLRX N/A
- 52 Week Low
- QSI $0.61
- PLRX $1.10
- 52 Week High
- QSI $5.77
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- QSI 47.34
- PLRX 48.01
- Support Level
- QSI $0.95
- PLRX $1.66
- Resistance Level
- QSI $1.16
- PLRX $1.85
- Average True Range (ATR)
- QSI 0.07
- PLRX 0.12
- MACD
- QSI 0.03
- PLRX -0.01
- Stochastic Oscillator
- QSI 65.22
- PLRX 33.33
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.